Last reviewed · How we verify
VRVg-2
VRVg-2 is a recombinant rotavirus vaccine candidate designed to prevent rotavirus gastroenteritis through immunization.
VRVg-2 is a recombinant rotavirus vaccine candidate designed to prevent rotavirus gastroenteritis through immunization. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | VRVg-2 |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated vaccine |
| Target | Rotavirus structural proteins (VP4, VP7) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
VRVg-2 is a live attenuated rotavirus vaccine that stimulates both humoral and mucosal immune responses against rotavirus antigens. By inducing protective antibodies and cellular immunity, the vaccine aims to prevent rotavirus infection and severe gastroenteritis, particularly in infants and young children in resource-limited settings.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (PHASE3)
- Immunogenicity and Safety of a Purified Vero Rabies Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VRVg-2 CI brief — competitive landscape report
- VRVg-2 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI